TY - BOOK TI - Alzheimer disease: Neuropsychology and pharmacology SN - 987654321 U1 - 616.831061 PY - 2003/// CY - Boston PB - Birkhauser Verlag KW - Alzheimer's disease KW - Chemotherapy N1 - Part I: Biological correlates of Alzheimer disease Alzheimer disease Introduction .. Differential diagnosis Alzheimer versus frontotemporal dementias . Semantic dementia Alzheimer versus dementia with Lewy bodies Epidemiology Risk factors ... Smoking history Sex Head trauma ... Cardiovascular risk factors .... Psychiatric manifestations Genetic susceptibility factors .. Herpes simplex virus infections Assessing outcome Discussion .. Neurological dysfunctions in Alzheimer disease Introduction . Neurochemical studies Senile plaques and neurofibrillary tangles . The p-amyloid precursor protein The amyloid cascade hypothesis.. Selective vulnerability.. Electrophysiological and imaging studies Magnetic resonance imaging Positron emission tomography ... Magnetization transfer ratio Discussion Pharmacology of Alzheimer disease Introduction Cholinergic receptors Cholinergic receptors and Ap deposition Monoaminergic receptors Serotonin Serotonin depletion studies.... Serotonin transporter Serotonin-cholinergic interaction Serotonin receptors and psychotic symptoms. Noradrenaline Noradrenergic-cholinergic interactions Dopamine Glutamate and NMDA receptors The cytokines Cyclo-oxygenase enzymes Metal-mediated oxy-radical and peroxide formation Neuroinflammation Oxidative stress Ap and endoplasmic reticulum-associated binding protein. A neurochemical marker for preclinical Alzheimer disease? CSF tau CSF cytokines Choline acetyltransferase activity Isoprostanes Calcium Serum anti-amyloid peptide antibodies Discussion Chapter 4: Molecular genetics of Alzheimer disease introduction Early onset Alzheimer disease . PS1 gene PS2 gene APP gene Interleukin genes Late-onset Alzheimer disease. Apolipoprotein E gene. Alpha-2 macroglobulin Tau immunoreactivities Genetic testing for Alzheimer disectse susceptibility Ethnic and racial differences... Discussion .. Promises of animal models of Alzheimer disease Introduction .. Transgenic models of mutant human (Hu) APR with Ap amyloid deposition . The Games mice.. The Hsiao mice ... The Novartis mice The CT100 mice .. Mutant presenilin mice .. Hu APP over-expression on the ApoE null background .. Hu APP over-expression combined with oxidative stress. APP knockout mice PS1 knockout mice Immunization with Ap.. Discussion Part II: Neuropsychoiogy of Alzheimer disease What is memory? Introduction Short-term memory, working memory and long-term memory Short-term memory Working memory The central executive system The phonological loop The visuospatial sketchpad .. The episodic buffer. Long-term memory. Declarative memory Episodic memory Semantic memory Autobiographical memory... Prospective memory Procedural memory. Skill learning Repetition priming. Controlled and automatic memory process. Neuroanatomy and physiology of memory. Medial-temporal and diencephalic systems. The amygdala The hippocampus The frontal lobes Amnesia Mental imaging Memory alterations in aging Discussion . Mild cognitive impairment Introduction Boundary between normal aging and MCl Neuropsychoiogical markers Eyeblink classical conditioning A standardized clinical assessment? Discussion ve impairment in Alzheimer disease Introduction Cognitive impairments.. Executive function Working memory deficit Episodic memory deficit Semantic memory deficit Naming deficit Intrusion errors Visuo-spatial deficit Language Memory distortions Implicit memory performance Cognitive differences in neurodegenerative disorders Typical Alzheimer disease. Frontotemporal dementia Semantic dementia Lewy body dementia Discussion oral and psychological impairments Introduction Psychological impairment. Anxiety Agitation and aggression ... Depression Psychosis Sexual impairment . Delirium Sleep disturbances.. Wandering Apathy.. Alterations in dietary habit. Discussion . Chapter 10: Assessment of memory Introduction Memory assessment The Alzheimer Disease Assessment Scale - Cognitive Subscale ... The Mini-Mental State Examination, The Blessed Dementia Scale The Gottfries-Brane-Steen Scale The Cambridge Mental Disorders of the Elderly Examination The 7-minute neurocognitive screening battery.... The Mattis dementia rating scale. The Brown-Peterson task The Cognitive Drug Research Computerized Assessment System Informant report questionnaire Choice of an appropriate sensitive cognitive test. Discussion . Chapter 11: Functional abilities and behavioral symptom assessments Introduction Functional abilities and activities of daily living assessment Blessed-Roth dementia scale Progressive deterioration scale Interview for deterioration in daily living activities in dementia.. AD Cooperative study-activities of daily living inventory Alzheimer disease functional assessment and change scale Disability assessment for dementia Behavioral assessment The dementia behavior disturbance The eating behavior scale Neuropsychiatric inventory Behavioral pathology in Alzheimer disease rating scale The Committee of the Consortium to establish a registry for Alzheimer disease The MOUSEPAD The Cohen-Mansfield agitation inventory. The geriatric mental state schedule The geriatric depression scale I The Cornell scale The consortium to establish a registry for AD behavior rating scale for dementia Global function assessment The clinical dementia rating scale The global interview-based change scale. The global deterioration scale AD cooperative study clinical global impression of change. Clinician's global impression of change Quality of life Concept of utilities. Discussion Part III: Treatment of Alzheimer disease Pharmacological treatments of cognitive deficits Introduction Modulation of the cholinergic system Tacrine Donepezil. Rivastigmine Metrifonate. Galantamine. Controlled-release physostigmine Nicotinic cholinergic strategies Modulation of other neurotransmitter systems.. Neurotrophic growth factors Decreasing the cellular reaction to neurodegeneration Propentofylline Drugs that reduce oxidative stress. Estrogen replacement therapy Therapeutic strategies in the APP/Ab amyloidgenic pathway Anti-inflammatory drugs Modulation of cholesterol homeostasis. Metal ion chelators The emerging field of pharmacogenetics Discussion Chapter 13: Pharmacological treatment of neuropsychiatric symptoms Introduction Depression.. Psychosis.... Anxiety Discussion .. Chapter 14: Psychological support and cognitive rehabilitation Introduction Cognitive rehabilitation Domain-specific knowledge — Errorless learning Action-based memory.. Reality orientation Metacognition improvement... Spaced retrieval Some other forms of treatment Imagery mnemonics. External aids. Discussion ... Chapter 15: Discussion and conclusion ER -